Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Trial details
- Registry ID
- NCT05257408
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408 | Corcept Therapeutics | Phase 3 | Active not recruiting | 2025-03-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |